Sanofi-Aventis' Adacel Launch Plans Await CDC Recommendations
This article was originally published in The Pink Sheet Daily
Executive Summary
FDA clears the tetanus, diphtheria, pertussis booster vaccine for individuals ages 11-64. Phase IV commitments include a concomitant use study with Sanofi's meningococcal vaccine Menactra.
You may also be interested in...
Boostrix And Adacel Get Universal Recommendation For 11-12 Year-Olds
CDC’s Advisory Committee on Immunization Practices also recommends catch-up Tdap vaccination for adolescents who have already received a Td booster. ACIP further recommends concomitant administration of Tdap with Sanofi-Aventis’ meningococcal conjugate vaccine Menactra.
Boostrix And Adacel Get Universal Recommendation For 11-12 Year-Olds
CDC’s Advisory Committee on Immunization Practices also recommends catch-up Tdap vaccination for adolescents who have already received a Td booster. ACIP further recommends concomitant administration of Tdap with Sanofi-Aventis’ meningococcal conjugate vaccine Menactra.
Teen Vaccine Approvals Increasing, FDA Says
The agency is observing a rise in the number of vaccines targeted at adolescents, CBER Vaccine Research & Review Director Baylor says. Two vaccines for use in adolescents – Menactra and Boostrix – have been approved so far this year; a third, Adacel, has a user fee date of June 11.